TP53 and neoplasm: On the basis of our study, we first reported that CLA could suppress OS progression by blocking LACTBM5L+R469K and propose that CLA is a promising anti‐tumor agent with less side effects for anti‐tumor via targeting LACTBM5L+R469K‐p53 pathway.